Teva’s deutetrabenazine fails in paediatric Tourette syndrome trials
Teva’s deutetrabenazine is indicated in the US to treat tardive dyskinesia in adults, and Huntington’s disease-related chorea. Credit: Open Grid Scheduler / Grid Engine.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more